InflaRx N.V. (NASDAQ:IFRX)’s earnings report is awaited on April, 4., Zacks reports. After $-0.31 EPS report previous quarter, Wall Street now predicts 41.94 % negative EPS growth of InflaRx N.V.. IFRX hit $39.18 during the last trading session after $0.56 change.InflaRx N.V. is uptrending after having risen 39.39% since March 29, 2018. IFRX has 180,902 volume or 49.82% up from normal. The stock outperformed the S&P500 by 35.02%.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe.The company has $1.02 billion market cap. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases.Last it reported negative earnings. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

For more InflaRx N.V. (NASDAQ:IFRX) news published briefly go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – GlobeNewswire” published on February 27, 2019, “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” on February 14, 2019, “InflaRx: Buy The Dip – Seeking Alpha” with a publish date: June 29, 2018, “InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” and the last “InflaRx Update: Pipeline Continues To Progress, Data In 1H 2019 – Seeking Alpha” with publication date: November 24, 2018.